Veeva Systemsは2026年第4四半期の収益予測を上回り,2027年の予測を上げ,買収と買い戻しを発表した. Veeva Systems beat earnings estimates in Q4 2026, raised 2027 guidance, and announced acquisitions and a buyback.

Veeva Systemsは2026年度の強大なQ4収益を報告し,2.06 EPSと836万ドルの収益は,両国が期待以上のものとして16%の成長を遂げた. Veeva Systems reported strong Q4 2026 earnings, with $2.06 EPS and $836 million in revenue, both exceeding expectations, driven by 16% year-over-year growth. 同社は,FY 2027 のガイドラインを8.85 ドル-00 EPSとQ1 2027 ^ 2.13 ドル-14 EPSに上げ,R&D及び安全の近代化を図る. The company raised FY 2027 guidance to $8.85–$9.00 EPS and Q1 2027 to $2.13–$2.14 EPS, citing demand in R&D and safety modernization. ベヴァは1億ドルの製薬契約を強化するためにAI-Ostroを買収し,AOPヘルスで大勝利を収め,5.5%の株式購入を発表した. Veeva acquired AI-driven Ostro for $100 million to boost pharma engagement, secured a major win with AOP Health, and announced a $5.5% share buyback. 株式取引は186.96ドルで 市場資本は30730億ドル Stock trades at $186.96 with a $30.73 billion market cap.